San Diego Biotech

Biotech Directory

Jul
21

Bullish biotechs shoot for $400M in another big week for IPOs

Posted under Atara Biotherapeutics, Biotech IPOs, Blog, Companies, Diagnostics, Funding, Innocoll, Medical Devices, Medical Supply, Pfenex, Pharmaceuticals, Startups, Universities, venture capital, Videos by Damian Garde

After Sage Therapeutics staged a stellar debut on Friday, 6 more drug developers are expected to price IPOs this week, looking to buck some bearish trends in biotech and raise about $400 million combined.

Jul
21

Will AbbVie now emerge as the next megamerger target?

Posted under AbbVie, Blog, Companies, Diagnostics, Funding, M&A, Medical Devices, Medical Supply, Pharmaceuticals, Shire, Startups, Universities, Videos by John Carroll

Now that AbbVie has hammered out its $55 billion takeover deal for Shire, analysts are looking for the next big biopharma tax inversion deal.

Jul
21

Cerecor raises $16M for PhII study of ‘Special K’ depression remedy

Posted under Blog, Cerecor, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Merck, Pharmaceuticals, R&D, Startups, Universities, Videos by John Carroll

Baltimore-based Cerecor has gathered up the first half of a $33 million B round, with plans to devote much of that money to a midstage development program for an experimental depression therapy recently punted by a restructuring Merck.

Jul
21

Biotech Stocks Shaken by Fed Warning

Posted under Blog, Companies, Diagnostics, Federal Reserve, Financial Times, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos by Pharm Exec

Today’s Financial Times (FT) reports that nearly $40bn was wiped from the biotech market’s value last week (a 6 per cent drop in the Nasdaq biotechnology index) following the Federal Reserve’s identification of biotech shares as a cause for concern. There was some recovery on Friday however when prices rebounded 3 per cent.

The US central bank has said biotech valuations in the sector appear to be stretched; the FT however points to analysts who argue that they “simply reflect the hoped-for higher growth rates, which can be astronomical”.

The FT also points out that investors “were pulling money out of the sector before the Fed issued its warning”. But the Nasdaq biotechnology index still remains 16 per cent above its low in April.

http://www.ft.com/cms/s/0/042a79aa-0e9b-11e4-ae0e-00144feabdc0.html?siteedition=uk#axzz386vzTbmf